ASX health stocks: EMV’s brain scanner is completed and ready for testing, stock price jumps 16pc
Health & Biotech
Health & Biotech
Link copied to
The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader index which rose by 0.35%.
Medical imaging specialist, EMVision (ASX:EMV), has rocketed by 16% after announcing that 1st Gen portable brain scanner has now been completed and ready for testing.
This is an interesting milestone for EMV, as the 1st Gen device is the company’s first model intended for commercialisation.
The device is targeted for use in ICUs, stroke and neurology wards, angiogram suites, and emergency departments.
What’s different about EMV’s brain scanner is that it’s portable and accessible, the company said.
It’s also unique in that it combines portable electromagnetic imaging technology and artificial intelligence (AI) to distinguish between ischaemic (blockage), and haemorrhagic (bleed) strokes in a matter of minutes.
Effectively, the device aims to fast track decision making, particularly within the critical “golden hour” from when a stroke occurs.
“We see an enormous market opportunity ahead in neuroimaging that is poised for disruption,” said EMVision CEO, Dr Ron Weinberger.
“Our device will undergo various tests as we prepare for our next stage of expanded clinical studies.”
The retinal disease specialist announced that recruitment is now open to patients in Canada for the Phase 3 clinical trial of OPT-302, treating wet (neovascular) age-related macular degeneration (AMD).
This pivotal Phase 3 trial has actually already begun in the US, and the latest expansion into Canada represents a new geographical region. Opthea is also currently working on ethics and regulatory approvals for other regions.
The US FDA had recently awarded OPT-302 Fast Track status, based on positive efficacy results from previous Phase 1/2 and Phase 2b clinical studies.
Real-world data has been published in the ‘International Wound Journal’ to compare the wound closure times for diabetic foot ulcers treated with either ARX’s Endoform Natural or collagen/ORC.
The finding shows the time to wound closure was 1.9 weeks faster in the Endoform Natural group relative to the collagen/ORC group.
The ARX share price rose by almost 2% on the news.
The cannabis company announced that its partnership with Monash University has completed an ethics submission for its phase 2a Psi-GAD study.
The study aims to combine psilocybin with specialised therapy to patients with Generalised Anxiety Disorder (GAD).
Simultaneously, Incannex has also submitted a comprehensive information package to the US FDA for the purpose of requesting a pre-IND meeting.
IHL rose by almost 4%.
Meanwhile, a handful of ASX health stocks rose by more than 2% after announcing management changes.